Five States Are Now Paying People to Stay Sober. It's Working.
Medicaid now covers contingency management in California, Delaware, Hawaii, Montana, and Washington. For a condition with no FDA-approved medications, it's the strongest evidence-based tool available.
There is no FDA-approved medication for methamphetamine use disorder. No pill, no injection, no patch. For the roughly 2.5 million Americans who use methamphetamine, the pharmacological toolkit that has transformed opioid treatment over the last two decades simply doesn’t exist. What does exist, with a larger and more consistent evidence base than almost any other behavioral intervention in addiction medicine, is contingency management: giving people tangible financial rewards when they test negative for their target substance.
The logic is behavioral — reinforce the behavior you want. The evidence is unusually strong: multiple meta-analyses, effect sizes that hold across populations and settings, a Washington State Institute for Public Policy analysis finding that CM programs offering more than $500 in total incentives have a 78% chance of generating benefits that exceed their costs. Among all psychosocial interventions for stimulant use disorder, contingency management has the most consistent empirical support.
Until recently, Medicaid — the primary payer for low-income Americans with substance use disorders — couldn’t fund it. The legal tangle around paying Medicaid beneficiaries cash-adjacent incentives, combined with federal anti-inducement provisions, kept CM out of most public-payer coverage. That’s been changing.
CMS has now approved Medicaid contingency management programs in five states: California, Delaware, Hawaii, Montana, and Washington. California’s Recovery Incentives Program — the first to launch as a formal Medicaid benefit — offers eligible members between $596 and $1,092 in financial incentives over the course of enrollment, depending on the duration and frequency of negative test results. Delaware extends CM services to pregnant and postpartum members for up to 64 weeks. Montana runs a 12-week program.
The January 2025 SAMHSA advisory allowing grantees to provide incentives up to $750 per patient per year removed another layer of the federal barrier.
What this means practically: the treatment gap for stimulant use disorder — which currently has no equivalent to buprenorphine for OUD — now has a first-line evidence-based option in five states. For a person with methamphetamine use disorder enrolled in Medicaid in California, there is now a structured path to paid participation in treatment that didn’t exist three years ago.
The question of why it’s still only five states is partly bureaucratic, partly political. Paying people to do things that are already their “responsibility” — staying sober, showing up for care — triggers a cultural resistance that has nothing to do with the evidence. That resistance has kept effective treatment unavailable for millions of people in 45 states where it could be deployed tomorrow, given political will.
The five-state picture is progress. It is not enough.
Related: Treatment & Recovery coverage · Stimulants
Sources Cited
- 01.BContingency Management: An Effective Framework for Treating Stimulant Use DisorderHealth Law & Policy Brief
- 02.A
- 03.AContingency Management for SUDHHS/ASPE
Filed Under
treatmentpolicyContingency ManagementMethamphetamineCocaine
Continue reading
More from this section
Prescribed Into a Corner: The Benzodiazepine Dependence Millions Don't Know They Have
Chronic benzodiazepine dependence affects millions prescribed the drugs appropriately. New February 2026 guidelines recommend 5-10% tapers every 2-4 weeks — far slower than typical clinical practice. But the people most affected are already years into protracted withdrawal syndrome, disbelieved by their doctors, managing their own detox with community guidance.
Treatment & RecoveryGift Cards, Urinalysis, and the Only Proven Tool for Meth: Why Contingency Management Is Finally Getting Its Due
Contingency management for stimulant use disorder is gaining clinical momentum but facing political headwinds. California's program must prove its value by year-end. Here's what the evidence actually shows.
Treatment & RecoveryThe First New Quit-Smoking Drug in Two Decades Is Ten Days from an FDA Decision
The FDA has until June 20 to approve cytisinicline, a plant-derived alkaloid from the laburnum tree with 60 years of European use. Two Phase 3 trials. The first potential new quit-smoking drug since Chantix in 2006.